Relmada Therapeutics, Inc. (RLMD)
Valuation Overview•Is Relmada Therapeutics, Inc. Overvalued or Undervalued?
The market is pricing the stock in line with historical averages, assuming steady-state growth.
Fragile underlying quality score of 32/100; weak margins or elevated debt leverage warrant caution.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Mixed fundamental profile with offsetting strengths and weaknesses.
Wall Street is highly bullish, projecting significant upside. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
RLMD struggles with subpar profitability and pressured margins. This is backed by a fortress balance sheet, holding significant net cash ($3M) and minimal debt risk.
The company maintains stable top-line performance paired with stable bottom-line earnings.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | — | — | — | — | |
| EBITDA | -$19.5M | — | +28.4% | — | — | |
| Net Income | -$19.1M | +28.2% | +28.5% | — | -34.4% | |
| EPS (Diluted) | $-0.22 | +45.3% | — | — | -3.5% | |
| Free Cash Flow | -$15.1M | +11.5% | +23.9% | -10.5% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | — | — | — | — |
| Operating Margin | — | — | — | — |
| Net Margin | — | — | — | — |
| FCF Margin | — | — | — | — |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $-0.18 | $-0.22 | -22.2% | ||
| Q1'26 | $-0.14 | $-0.27 | -92.9% | ||
| Q4'25 | $-0.04 | $-0.30 | -650.0% | ||
| Q3'25 | $-0.25 | $-0.30 | -20.0% | ||
| Q2'25 | $-0.31 | $-0.58 | -87.1% | ||
| Q1'25 | $-0.70 | $-0.62 | +11.4% | ||
| Q4'24 | $-0.65 | $-0.72 | -10.8% | ||
| Q3'24 | $-0.83 | $-0.59 | +28.9% |
Total return is +999.0% (1Y), outperforming the benchmark by +978.2%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +48.9% | +41.5% | — |
| 1Y | +999.0% | +978.2% | — |
| 3YCAGR | +119.2% | +102.8% | — |
| 5YCAGR | -0.5% | -10.5% | — |
| 10YCAGR | +12.4% | -1.4% | — |
The S&P 500 is at 31.0x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Relmada Therapeutics, Inc. (RLMD) valuation, health, and returns.
Relmada Therapeutics, Inc. valuation is being assessed using available models.
Relmada Therapeutics, Inc. has multiple valuation anchors: Wall Street Analyst Target: $10.00 (implying +43.3% upside). A convergence of these signals offers higher conviction.
Relmada Therapeutics, Inc. displays weak financial health with a composite quality score of 32/100, supported by a Altman Z-Score of 29.6 (safe zone), Piotroski F-Score of 3/9, Return on Invested Capital (ROIC) of -77.3%.
Relmada Therapeutics, Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Relmada Therapeutics, Inc.'s current growth trajectory is Stable. The company achieved N/A 1Y revenue growth and +45.3% 1Y EPS growth, compared to its 3Y revenue CAGR of N/A.
Wall Street consensus is Buy based on 8 analysts, beating EPS expectations in 50% of recent quarters with a -5-quarter streak. The consensus price target represents a +43.3% change from current levels.
Investment risks for Relmada Therapeutics, Inc. include: -27.4% 1-year max drawdown, high beta (1.56x market volatility). Volatility risk is characterized by a beta of 1.56x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.